VistaGen Therapeutics Company Presentation

14 t = 3.16 p = 0.002 Cohen’s d (Effect Size) .66 PH94B Phase 2 SAD Study – Public Speaking (n = 91) Active Group: Mean Difference = 26.7 Standard Deviation = 21.6 Number of Subjects = 45 Placebo Group: Mean Difference = 14.0 Standard Deviation = 16.3 Number of subjects = 46 PH94B Rapidly Reduced Anxiety in Response to Public Speaking Challenge Liebowitz, MR, Salman, E, Nicolini, H, Rosenthal, N, Hanover, R, Monti. L (2014). Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder. Am. J. Psychiatry 171:675-682.